MDGL Similar Chart Price Prediction
The price of MDGL is predicted to go up -1.25%, based on the high correlation periods with MAYS. The similarity of these two price pattern on the periods is 90.35%.
MDGL
MAYS
Down: -1.25%Similarity: 90.35%
MDGL Revenue Forecast
MDGL EPS Forecast
MDGL FAQs
What is bull’s view on MDGL?
What is bear's view on MDGL?
What is MDGL revenue forecast for next quarter？
What is MDGL eps forecast for next quarter？
MDGL Analyst's Forecast
Mayank Mamtani
B. Riley Securities
Hold
2024-11-05
Price Target
$194 → $236
Downside
-30.1%
B. Riley analyst Mayank Mamtani raised the firm's price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal's Q3 earnings "blowout" print reaffirmed Rezdiffra's robust early launch trends in advanced nonalcoholic steatohepatitis patients and competitor Novo Nordisk's (NVO) positive Phase III ESSENCE liver biopsy readout a net positive at large for the MASH therapeutics' landscape and drove a 40% equity move, the analyst tells investors in a research note. Further upside for Madrigal is limited, however, due to flattening Rezdiffra new prescriptions and the floodgates opened for multiple next-gen GLP1 based therapies, the firm says.
Eliana Merle
UBS
Strong Buy
2024-11-01
Price Target
$411 → $441
Upside
+37.99%
Jay Olson
Oppenheimer
Buy
2024-10-23
Price Target
$375 → $350
Upside
+72.86%
